ADXS (news update) AXAL EMA application is withdrawn prompting a multi-day swoom to 52-WL. Parnered Ph1/2 study with AZN gets clinical hold lifted. This is an AXAL-PDL1 antibody combo study. Stock spikes premarket and sells off all day.